Sanofi and GSK announced today the initiation of a new phase 2 study of their adjuvanted recombinant protein COVID-19 vaccine candidate. The study will evaluate the candidate's safety, reactogenicity, and immunogenicity, and if successful, will support selection of the most appropriate antigen dosage for phase 3.
Two vaccine candidates against COVID-19
As the pandemic continues, Sanofi is pursuing vaccine development, while carrying on the daily business of making and delivering medicines for patients
How Sanofi COVID-19 vaccine candidates are designed
Sanofi is taking a two-pronged approach to vaccine development to help meet global public health needs during the coronavirus pandemic.